|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.32 USD | +0.11% |
|
+5.08% | -35.15% |
| 03/06 | Oppenheimer Adjusts Immunovant Price Target to $46 From $50, Maintains Outperform Rating | MT |
| 30/05 | Sector Update: Health Care Stocks Mixed Pre-Bell Thursday | MT |
Immunovant, Inc. reported earnings results for the full year ended March 31, 2024. For the full year, the company reported net loss was USD 259.34 million compared to USD 210.96 million a year ago. Basic loss per share from continuing operations was USD 1.88 compared to USD 1.71 a year ago.
Diluted loss per share from continuing operations was USD 1.88 compared to USD 1.71 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -35.15% | 399.02Cr | |
| +34.14% | 5.11TCr | |
| -6.54% | 3.94TCr | |
| +34.92% | 3.85TCr | |
| +12.62% | 2.64TCr | |
| -12.11% | 2.62TCr | |
| -13.43% | 2.1TCr | |
| +43.73% | 1.4TCr | |
| +31.81% | 1.25TCr | |
| -4.54% | 1.16TCr |
IMMUNOVANT, INC. 
